Flexibilities in controlled substances prescribing and dispensing during the COVID-19 pandemic

Flexibilities in controlled substances prescribing and dispensing during the COVID-19 pandemic

Collection:
Health Policy and Services Research
Series Title(s):
ASPE issue brief
Contributor(s):
United States. Department of Health and Human Services. Office of Science and Data Policy, issuing body.
Publication:
Washington, D.C. : Assistant Secretary for Planning and Evaluation, Office of Science & Data Policy, August 2022
Language(s):
English
Format:
Text
Subject(s):
Controlled Substances -- supply & distribution
COVID-19
Electronic Prescribing
Federal Government
Health Services Accessibility
Opiate Substitution Treatment
State Government
United States
Genre(s):
Technical Report
Abstract:
The federal government issued a range of flexibilities around telehealth, medications for opioid use disorder, licensing, and emergency prescribing to improve access to controlled substances and medications for opioid use disorder during the COVID-19 pandemic. States relaxed or suspended regulations to allow for the implementation of federally-issued flexibilities, and also issued unique flexibilities related to controlled substance prescribing. Flexibilities allowing for the use of telehealth for controlled substance prescribing and medications for opioid use disorder were the most common flexibilities implemented by states. This brief summarizes federal and state flexibilities around controlled substance prescribing in response to the COVID-19 pandemic, enabling analysis of the impacts on prescribing and patient access.
Copyright:
The National Library of Medicine believes this item to be in the public domain. (More information)
Extent:
1 online resource (1 PDF file (9 pages))
Illustrations:
Illustrations
NLM Unique ID:
9918539488306676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918539488306676